RxDoctor Payments Data

Christine Sabitsky, PA

Physician Assistant · Allentown, PANPI 1619287901

Payments from drug & device makers

$2,177in general payments, 2019–2025

Across 114 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$756
  • Johnson & Johnson$458
  • E.r. Squibb & Sons, L.L.C.$430
  • Sanofi$310
  • LEO Pharma Inc.$60
  • Novartis$51
  • plus $112 from 3 others

What the payments were for

  • Food & beverage$1,85385%
  • Education$32415%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,177 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$144,166
Medicare patients
803
Services billed
2,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast37$159,615
Calcipotriene22$5,310
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc70$4,985
Ketoconazole208$4,823
Clobetasol Propionate77$3,729
Metronidazole55$3,274
Fluorouracil40$2,537
Doxycycline Hyclate48$1,341
Triamcinolone Acetonide106$957
Clindamycin Phosphate20$730
Hydrocortisone122$633
Betamethasone Dipropionate18$603
Desonide12$325
Mupirocin20$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$38$159,61537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →